20 result(s) for Lung Cancers
| PI Name | Protocol # | Title |
|---|---|---|
| Jeremy Cetnar | IRB00011046 | [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer |
| Jacqueline Vuky | IRB00011804 | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors |
| Jeremy Cetnar | IRB00011845 | A Phase III, Open-Label Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer |
| Jeremy Cetnar | STUDY00015662 | CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy |
| Jeremy Cetnar | STUDY00016349 | [Advarra – IAA] CINC280A2201: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) |
| Jeremy Cetnar | STUDY00016887 | A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy |
| Eric Anderson | STUDY00017574 | A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial |
| Rajan Kulkarni | STUDY00017648 | VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens |
| Jeremy Cetnar | STUDY00017685 | CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC |
| Timur Mitin | STUDY00018029 | Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer |
| Jeremy Cetnar | STUDY00019009 | A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer |
| Jeremy Cetnar | STUDY00019101 | STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS MAINTENANCE TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC) |
| Jeremy Cetnar | STUDY00019330 | A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007) |
| Jeremy Cetnar | STUDY00019434 | [NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer |
| Jeremy Cetnar | STUDY00019505 | A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer |
| Eric Anderson | STUDY00019537 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) |
| Jeremy Cetnar | STUDY00019556 | [NCI CIRB] S1900A - A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRAC1/2 Mutation Stage IV or Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub Study) |
| Christopher Ryan | STUDY00019992 | [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH) |
| Jeremy Cetnar | STUDY00020077 | [NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study) |
| Eneida Nemecek | STUDY00020379 | Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
You may also qualify for Phase 1 Program trials.